title: The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.
abstract: The first transgenic mouse of the TCL1 oncogene was described more than 15 years ago, and since then, the overexpression of the gene in T- and B-cells in vivo has been extensively studied to reveal the molecular details in the pathogenesis of some lymphocytic leukemias. This review discusses the main features of the original TCL1 models and the different lines of research successively developed with particular attention to genetically compound mice and the therapeutic applications in drug development.
authors.affiliation: MVIMG, The Ohio State University, Columbus, OH, USA.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Pekarsky
authors.forename: Alessandra
authors.initials: A
authors.lastname: Drusco
authors.forename: Prasanthi
authors.initials: P
authors.lastname: Kumchala
authors.forename: Carlo M
authors.initials: CM
authors.lastname: Croce
authors.forename: Nicola
authors.initials: N
authors.lastname: Zanesi
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D055808:Drug Discovery; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology
chemical_list: D011518:Proto-Oncogene Proteins; C490393:Tcl1 protein, mouse